[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653729":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":25,"overallOfficials":31,"centralContacts":34,"locations":11,"responsibleParty":42,"collaborators":11,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":11,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":11},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants treated",null,"Up to approximately 28 days after last dose of deucravacitinib",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NA","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":11,"interventionNames":23},"Deucravacitinib Arm","EXPERIMENTAL",[24],"Drug: Deucravacitinib",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","Deucravacitinib","Specified dose on specified days",[21],[32],{"name":5,"affiliation":5,"role":33},"STUDY_DIRECTOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":41,"role":37,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653729","phase-3-continued-access-to-deucravacitinib-for-adult-slesjd-and-pediatric-psopsa-study-completers-100653729",false,"NCT07791199","Continued Access to Deucravacitinib for Adult SLE\u002FSjD and Pediatric PsO\u002FPsA Study Completers","A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies","Inclusion Criteria:\n\n* Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.\n\nExclusion Criteria:\n\n* Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","4 Years","75 Years",{"count":55,"type":56},2300,"ESTIMATED","INTERVENTIONAL",[59],"PHASE3","This study is designed to provide treatment with deucravacitinib for participants with SLE\u002FSjD (Systemic Lupus Erythematosus\u002FSjögren's Disease) and pediatric participants with PsO\u002FPsA (Psoriasis\u002FPsoriatic Arthritis) who have completed their qualified parent studies and\u002For long-term extension if applicable.",[62,63,64,65],"Systemic Lupus Erythematosus","Sjögren's Disease","Psoriasis","Psoriatic Arthritis",[67,68,69,70,71,72,73,74,75,76,77,78,28,79],"SLE","SJD","SJS","PSO","PSA","POETYK","POETYK-1","POETYK-2","POETK-SJS","jPSA","Pediatric","Juvenile","SOTYKTU","NOT_YET_RECRUITING","2026-09-02",{"date":83,"type":84},"2026-09-03","ACTUAL",{"date":86,"type":56},"2026-12-31",{"date":88,"type":56},"2030-10-31",{"name":5,"class":6}]